Vitamin D intake and risk of CVD and all-cause mortality: evidence from the Caerphilly Prospective Cohort Study by Guo, Sarah et al.
Vitamin D intake and risk of CVD and all­
cause mortality: evidence from the 
Caerphilly Prospective Cohort Study 
Article 
Published Version 
Creative Commons: Attribution 4.0 (CC­BY) 
Open Access 
Guo, S., Cockcroft , J. R., Elwood, P. C., Pickering, J. E., 
Lovegrove, J. A. and Givens, D. I. (2017) Vitamin D intake and 
risk of CVD and all­cause mortality: evidence from the 
Caerphilly Prospective Cohort Study. Public Health Nutrition. 
ISSN 1368­9800 doi: 
https://doi.org/10.1017/S1368980017001732 Available at 
http://centaur.reading.ac.uk/72124/ 
It is advisable to refer to the publisher’s version if you intend to cite from the 
work. 
To link to this article DOI: http://dx.doi.org/10.1017/S1368980017001732 
Publisher: Cambridge University Press 
All outputs in CentAUR are protected by Intellectual Property Rights law, 
including copyright law. Copyright and IPR is retained by the creators or other 
copyright holders. Terms and conditions for use of this material are defined in 
the End User Agreement . 
www.reading.ac.uk/centaur 
CentAUR 
Central Archive at the University of Reading 
Reading’s research outputs online
Vitamin D intake and risk of CVD and all-cause mortality:
evidence from the Caerphilly Prospective Cohort Study
Jing Guo1,*, John R Cockcroft2, Peter C Elwood3, Janet E Pickering1, Julie A Lovegrove1,4
and David I Givens1
1Institute for Food, Nutrition and Health, University of Reading, Reading RG6 6AR, UK: 2Wales Heart Research
Institute, Cardiff University, Cardiff, UK: 3Department of Primary Care and Public Health, Cardiff University,
Cardiff, UK: 4Hugh Sinclair Unit of Human Nutrition and Institute for Cardiovascular and Metabolic Research, Faculty
of Life Sciences, University of Reading, Reading, UK
Submitted 31 January 2017: Final revision received 11 June 2017: Accepted 16 June 2017
Abstract
Objective: Prospective data on the associations between vitamin D intake and risk
of CVD and all-cause mortality are limited and inconclusive. The aim of the
present study was to investigate the associations between vitamin D intake and
CVD risk and all-cause mortality in the Caerphilly Prospective Cohort Study.
Design: The associations of vitamin D intake with CVD risk markers were
examined cross-sectionally at baseline and longitudinally at 5-year, 10-year and
>20-year follow-ups. In addition, the predictive value of vitamin D intake for CVD
events and all-cause mortality after >20 years of follow-up was examined. Logistic
regression and general linear regression were used for data analysis.
Setting: Participants in the UK.
Subjects: Men (n 452) who were free from CVD and type 2 diabetes at recruitment.
Results: Higher vitamin D intake was associated with increased HDL cholesterol
(P= 0·003) and pulse pressure (P= 0·04) and decreased total cholesterol:HDL
cholesterol (P= 0·008) cross-sectionally at baseline, but the associations were lost
during follow-up. Furthermore, higher vitamin D intake was associated with
decreased concentration of plasma TAG at baseline (P= 0·01) and at the 5-year
(P= 0·01), but not the 10-year examination. After >20 years of follow-up, vitamin
D was not associated with stroke (n 72), myocardial infarctions (n 142), heart
failure (n 43) or all-cause mortality (n 281), but was positively associated with
increased diastolic blood pressure (P= 0·03).
Conclusions: The study supports associations of higher vitamin D intake with
lower fasting plasma TAG and higher diastolic blood pressure.
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TAG
Recently, the UK Scientiﬁc Advisory Committee on Nutrition(1)
reported that 22–24% of individuals aged 19–64 years and
17–24% of those aged ≥65 years in the UK were vitamin D
deﬁcient (plasma 25-hydroxycholecalciferol <25nmol/l).
People generally obtain vitamin D from synthesis in the skin
due to sunlight UV radiation and/or foods. However, a
number of relatively recent lifestyle changes (increased
working indoors, sunscreen use), personal characteristics
(ageing, skin pigmentation) and geographic reasons (latitude)
limit the ability to synthesise adequate vitamin D from sun-
light(2). As a result, vitamin D intake from foods has become
more important than previously. This led the Scientiﬁc Advi-
sory Committee on Nutrition to recommend a daily vitamin D
intake of 10µg for all adults within the UK(1).
CVD is one of the main causes of morbidity and mortality
in the world and there is mounting evidence indicating an
association between suboptimal vitamin D status and
increased risk of CVD(3–6) and all-cause mortality(7–9).
However, few prospective cohort studies have analysed the
relationship between vitamin D intake and CVD risk and all-
cause mortality. In a 10-year cohort of 361 men and 394
women(10), lower vitamin D intake was associated with an
increased risk of stroke, but not myocardial infraction (MI).
Furthermore, higher vitamin D intake was found to be
associated with increased risk of CVD in a large US cohort of
74 272 women and 44 592 men(11). In contrast, it was
reported by two further prospective cohort studies of 34 486
postmenopausal Iowa women(12) and 1529 Australians(13)
that vitamin D intake was not associated with CVD mortality.
The evidence on the association of vitamin D intake
with CVD risk or all-cause mortality from prospective
cohort studies is limited; we therefore investigated the
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associations between vitamin D intake and CVD events,
CVD risk markers and all-cause mortality using the
Caerphilly Prospective Cohort Study (CAPS) which has
over 20 years of follow-up.
Methods
Study population
CAPS was initially set up in 1979–1983 to investigate the
CVD risk factors based on 2512 men (45–59 years), repre-
senting 89% of the subjects living in Caerphilly and the
adjacent area(14), who were followed up at 5-year intervals.
At Phase 2 (1984–1988), 561 men were lost from Phase 1
(1979–1983) and an additional 447 men were recruited to
follow up. In Phase 1, a representative 30% sub-sample of
subjects (665 men) was randomly selected at baseline to
complete a 7 d weighed dietary intake record(15). Food items
were coded according to McCance and Widdowson(16).
These men were given weighing scales with instructions on
how to complete the weighed dietary intake for seven
consecutive days. From these records vitamin D intake was
estimated based on food composition data given by
McCance and Widdowson(16); additionally, several manu-
facturers were contacted to obtain more information on new
foodstuffs containing mixtures of ingredients(15,17). To
ensure consistency of the subject group throughout the
study, the 134 men from the weighed intake subgroup who
dropped out after Phase 1 were excluded from the current
analysis. In addition, seventeen subjects who previously had
a heart attack and sixty-two subjects with missing con-
founding factor data were excluded. Therefore, a total of
452 subjects were available for the current analysis.
CVD events and all-cause mortality
Identiﬁcation of stroke and vascular disease events has
been described elsewhere(18,19). Symptoms and illnesses
suggestive a heart attack or stroke were conﬁrmed
according to the London School of Hygiene chest pain
questionnaire and the Oxford Stroke Questionnaire. In
addition, subjects were invited to clinics for an electro-
cardiogram measurement. Identiﬁcation of fatal and
non-fatal vascular disease events (ICD-10 (International
Classiﬁcation of Diseases, 10th revision) codes 121–5)
including MI, heart failure and stroke (ICD-10 codes 163–4)
were diagnosed by two independent expert clinicians and
an epidemiologist using clinical evidence of computed
tomography, pathological and radiological information.
Furthermore, incidents of all-cause mortality were censored
by the National Health Service Central Registry. Cause of
death was deﬁned according to ICD-9 (International
Classiﬁcation of Diseases, 9th revision).
Cardiovascular risk markers
Fasting blood samples were taken at baseline, 5 years and
10 years to measure a wide range of CVD risk markers(14).
Plasma glucose and TAG were measured at baseline,
5-year and 10-year examinations; however, the ratio of
total cholesterol (TC) to HDL cholesterol (HDL-C) and
insulin were measured only at baseline and the 5-year
examination.
After over 20 years of follow-up (until present), the
haemodynamic variables of systolic blood pressure (SBP),
diastolic blood pressure (DBP), aortic pulse wave velocity,
augmentation index and mean arterial pressure were
measured as described in detail elsewhere(20,21). SBP
and DBP were measured at each visit: baseline, 5 years,
10 years and 20 years(14). Pulse pressure was calculated by
subtracting DBP from SBP. The Friedewald formula(22)
was used to calculate LDL cholesterol.
Statistical analyses
Data were analysed using the statistical software package
Stata version 13.0 (2014). Our primary analysis investi-
gated the longitudinal relationship between baseline
vitamin D intake and CVD events (including stroke,
MI and heart failure) and all-cause mortality after over
20 years of follow-up. Analyses of baseline vitamin D
intake with CVD risk markers cross-sectionally at baseline,
and longitudinally at 5-year or 10-year follow-up, were the
secondary analyses. The subjects were divided into four
groups according to vitamin D intake. Logistic regression
and general linear regression statistical models were used
to investigate the relationships of vitamin D intake with
categorical and continuous variables of CVD risk markers,
respectively. In addition, logistic regression analyses were
used to estimate the OR of stroke, MI, heart failure and
all-cause mortality. The ﬁrst multivariate-adjusted model
for all analyses included the confounding factors of age
(years), BMI (kg/m2), social class (manual worker; non-
manual worker), smoking (current smoker; never smoked;
ex-smoker), leisure activity (with heavy work or exercise
in leisure time; without heavy work or exercise in leisure
time), alcohol (as ethanol, ml/week) and food energy
intake (MJ/d). In addition, as vitamin D is functionally
closely related with Ca, the second multivariate-adjusted
model was further adjusted for Ca intake. For skewed
variables, original data were transformed to natural loga-
rithms for the regression model. The β coefﬁcient was
used to represent the change in the dependent variable for
a 1 SD change in the exposure. Results were considered
statistically signiﬁcant at P< 0·05.
Results
The characteristics of the 452 subjects at baseline are
shown in Table 1. The mean vitamin D intake was 21·0
(SD 19·3) µg/week. Subjects in the lowest quartiles of
vitamin D intake were signiﬁcantly more likely to be
smokers (P= 0·001) and had lower food energy intake
(P< 0·001). After controlling for total energy intake from
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foods, those with the highest weekly vitamin D intake
tended to have higher intakes of fat (P= 0·002), cereal
ﬁbre (P< 0·001), vegetable ﬁbre (P< 0·001) and Ca
(P< 0·001). There were no associations between vitamin D
intake and age, BMI, social class, leisure activity, alcohol
consumption, protein intake and carbohydrate intake.
Associations of vitamin D intake with different CVD risk
markers were investigated at baseline as a cross-sectional
analysis. There was a signiﬁcant positive association
between vitamin D intake and HDL-C (adjusted model 1:
P= 0·002; adjusted model 2: P= 0·003; Table 2), with
subjects consuming the highest vitamin D intake
(≥27·3 µg/week) having 0·13mmol/l higher mean HDL-C
levels compared with subjects consuming the lowest
vitamin D intake (0·1–9·9 µg/week). In addition, negative
associations were observed between vitamin D intake and
TC:HDL-C (adjusted model 1: P= 0·005; adjusted model 2:
P= 0·008) and TAG concentration (adjusted model 1:
P= 0·003; adjusted model 2: P= 0·01), with the subjects
consuming ≥27·3 µg vitamin D/week having 0·7mmol/l:
mmol/l lower mean TC:HDL-C and 0·5mmol/l lower
mean plasma TAG compared with subjects consuming the
lowest vitamin D intake (0·1–9·9 µg/week). Also, a modest
positive trend was found between vitamin D intake and
pulse pressure (adjusted model 1: P= 0·03; adjusted model
2: P= 0·04).
In the longitudinal analyses of vitamin D intake and
CVD risk markers at the 5-year examination, higher
vitamin D intake was signiﬁcantly negatively associated
with plasma TAG concentration (adjusted model 1:
P= 0·003; adjusted model 2: P= 0·01; Table 3). Subjects
consuming the highest vitamin D intake (≥27·3 µg/week)
had 0·48mmol/l lower mean plasma TAG than subjects
consuming the lowest vitamin D intake (0·1–9·9 µg/week).
There were no signiﬁcant associations between vitamin D
intake and other CVD risk markers at the 5-year
examination. In the longitudinal analyses at the 10-year
examination, there were no associations between vitamin
D intake and CVD risk markers (Table 4).
After over 20 years of follow-up (mean follow-up is 22·8
years), a tendency for a lower pulse pressure was seen in
those with the highest vitamin D intake, but this did not
reach signiﬁcance (Table 5). In the analyses of the asso-
ciations of SBP and DBP with vitamin D intake, DBP
showed a positive correlation with vitamin D intake in the
multivariate-adjusted models (adjusted model 1: P= 0·04;
adjusted model 2: P= 0·03), but no signiﬁcant associations
were found between vitamin D intake and SBP.
There were no signiﬁcant associations between vitamin
D intake and other CVD risk markers: fasting glucose/
insulin (see online supplementary material, Supplemental
Tables 1–3), mean arterial pressure, pulse wave velocity
and augmentation index (Table 5). Also, there were no
signiﬁcant associations of vitamin D intake and cardio-
vascular events (stroke, MI, heart failure) or all-cause
mortality after over 20 years of follow-up (Table 6).
Discussion
In the present UK prospective cohort study of middle-aged
men with over 20 years of follow-up, we found higher
vitamin D intake was associated with lower plasma TAG
concentration after cross-sectional analysis at baseline and
longitudinally at the 5-year follow-up, but not at the
10-year follow-up. After over 20 years of follow-up, a
modest positive association was found between vitamin D
intake and DBP. In contrast, no associations were found
between vitamin D and other metabolite markers or disease
outcomes of stroke, MI, heart failure and all-cause mortality.
To our knowledge, the present study is the ﬁrst pro-
spective study to investigate the associations between
P
u
b
lic
H
ea
lt
h
N
u
tr
it
io
n
Table 1 Baseline characteristics (n 452) of participants by category of vitamin D intake, Caerphilly Prospective Cohort Study
Vitamin D intake from foods (µg/week)
0·1–9·9 10·0–15·1 15·2–27·2 ≥27·3
Characteristic Mean SD Mean SD Mean SD Mean SD P for trend
Subjects, (n ) 114 – 112 – 114 – 112 –
Age (years) 52 4·5 52 4·1 51 4·4 52 4·6 0·74
BMI (kg/m2) 26·3 3·1 25·9 3·1 26·3 3·6 26·1 3·1 0·78
Leisure activity (%) 43·9 – 52·7 – 50·0 – 57·1 – 0·08
Manual workers (%) 68·4 – 49·1 – 63·2 – 70·5 – 0·33
Current smokers (%) 64·9 – 58·0 – 50·9 – 44·6 – 0·001
Energy intake (MJ/d) 6·5 1·7 7·3 1·6 7·3 1·6 7·6 1·5 <0·001
Fat (% of food energy) 36·0 6·2 36·5 6·0 38·1 4·8 37·9 5·1 0·002
Protein (% of food energy)* 13·9 2·7 13·5 2·3 13·8 2·4 14·0 2·4 0·25
Carbohydrate (% of food energy)* 45·7 8·2 46·1 7·5 46·6 5·8 45·0 6·6 0·60
Alcohol intake (ml ethanol/week)† 37·0 62·7 32·2 38·7 21·7 27·7 29·0 35·0 0·11
Fibre, vegetable sources (g/d)† 8·2 0·3 8·4 0·2 8·5 0·3 8·6 0·3 <0·001
Fibre, cereal sources (g/d)† 7·3 1·4 7·9 1·1 8·1 1·2 9·1 1·2 <0·001
Ca intake (mg/week)† 5567 268 6343 200 6335 225 6613 224 <0·001
*Original data were transformed to natural logarithms for regression model.
†Data were adjusted for energy intake from foods.
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vitamin D intake and blood lipid proﬁle in a generally
healthy population using both cross-sectional and longi-
tudinal analyses. The negative association between
vitamin D intake and plasma TAG at baseline and the
5-year examination is similar to that seen in a study(23)
which involved weight reduction and daily supplementa-
tion with vitamin D (83 µg) in healthy overweight subjects
for over 12 months. This resulted in TAG concentration
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Table 2 Cross-sectional analysis between baseline vitamin D intake and markers of CVD risk, Caerphilly Prospective Cohort Study
Vitamin D intake from foods (µg/week)
Characteristic 0·1–9·9 10·0–15·1 15·2–27·2 ≥27·3 P for trend
Total cholesterol
Participants (n) 114 112 114 112
Mean (mmol/l) 5·98 5·99 5·93 5·81
SD 1·11 1·56 1·08 0·94
Unadjusted coeff. Ref. 0·001 0·053 0·174 0·25
Multivariable-adjusted β coeff.* Ref. 0·012 0·025 0·109 0·49
Multivariable-adjusted β coeff.† Ref. 0·029 0·007 0·083 0·59
HDL cholesterol
Participants (n) 112 110 113 111
Mean (mmol/l) 1·29 1·32 1·40 1·42
SD 0·37 0·34 0·40 0·41
Unadjusted coeff. Ref. 0·025 0·104 0·122 0·006
Multivariable-adjusted β coeff.* Ref. 0·023 0·129 0·134 0·002
Multivariable-adjusted β coeff.† Ref. 0·020 0·126 0·131 0·003
Total cholesterol:HDL cholesterol‡
Participants (n) 112 110 113 111
Mean (mmol/l:mmol/l) 5·13 4·83 4·53 4·43
SD 2·40 1·92 1·35 1·42
Unadjusted coeff. Ref. 0·045 0·094 0·120 0·004
Multivariable-adjusted β coeff.* Ref. 0·039 0·102 0·112 0·005
Multivariable-adjusted β coeff.† Ref. 0·035 0·098 0·107 0·008
LDL cholesterol
Participants· (n) 112 108 103 109
Mean (mmol/l) 4·30 4·28 4·21 4·09
SD 1·12 1·51 1·08 0·98
Unadjusted coeff. Ref. 0·017 0·087 0·202 0·18
Multivariable-adjusted β coeff.* Ref. 0·018 0·089 0·159 0·30
Multivariable-adjusted β coeff.† Ref. 0·007 0·077 0·142 0·35
TAG‡
Participants (n) 112 108 113 110
Mean (mmol/l) 2·06 1·81 1·62 1·56
SD 1·20 1·21 0·91 0·98
Unadjusted coeff. Ref. 0·130 0·206 0·262 <0·001
Multivariable-adjusted β coeff.* Ref. 0·098 0·163 0·214 0·003
Multivariable-adjusted β coeff.† Ref. 0·075 0·138 0·180 0·01
Systolic blood pressure
Participants (n) 114 112 114 112
Mean (mmHg) 140·5 139·8 141·6 140·6
SD 20·9 18·1 20·1 17·0
Unadjusted coeff. Ref. 0·678 1·114 0·045 0·81
Multivariable-adjusted β coeff.* Ref. 0·934 2·994 1·123 0·49
Multivariable-adjusted β coeff.† Ref. 1·066 3·136 1·321 0·45
Diastolic blood pressure
Participants (n) 114 112 114 112
Mean, mmHg 89·4 90·1 88·7 87·4
SD 12·0 11·7 12·4 11·9
Unadjusted coeff. Ref. 0·615 0·754 2·064 0·14
Multivariable-adjusted β coeff.* Ref. 1·237 0·471 1·935 0·15
Multivariable-adjusted β coeff.† Ref. 1·567 0·113 1·438 0·25
Pulse pressure
Participants (n) 114 112 114 112
Mean (mmHg) 51·1 49·8 53·0 53·2
SD 14·5 13·6 13·2 13·8
Unadjusted coeff. Ref. 1·293 1·868 2·109 0·10
Multivariable-adjusted β coeff.* Ref. 0·303 3·465 3·058 0·03
Multivariable-adjusted β coeff.† Ref. 0·501 3·250 2·760 0·04
Coeff., coefficient; ref., reference category.
*Multivariable-adjusted model 1, adjusted for age, BMI, social class (manual and non-manual workers), alcohol intake (non-drinker, drinker has been divided
into three equal groups), smokers (non-smoker, current smoker, previous smoker), leisure activity (yes and no) and food energy intake.
†Multivariable-adjusted model 2, additionally adjusted for Ca intake.
‡Original data were transformed to natural logarithms for regression model.
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decreasing by 13·5% in the treatment group, yet increasing
by 3% in the placebo group (P< 0·001), and the vitamin D
supplement did not adversely affect the loss of weight(23).
Our results are also in line with the ﬁndings of a 6-month
randomised controlled trial(24) in postmenopausal women
with type 2 diabetes, which showed that a daily 100 µg
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Table 3 Longitudinal analysis between baseline (Phase 1) vitamin D intake and markers of CVD risk after 5 years of
follow-up, Caerphilly Prospective Cohort Study
Vitamin D intake from foods (µg/week)
Characteristic 0·1–9·9 10·0–15·1 15·2–27·2 ≥27·3 P for trend
Total cholesterol
Participants (n) 109 110 111 109
Mean (mmol/l) 5·67 5·62 5·68 5·60
SD 0·96 1·08 0·97 0·84
Unadjusted coeff. Ref. −0·045 0·018 −0·068 0·73
Multivariable-adjusted β coeff.* Ref. −0·018 0·042 −0·025 0·98
Multivariable-adjusted β coeff.† Ref. 0·027 0·086 0·038 0·69
HDL cholesterol
Participants (n) 109 110 111 109
Mean (mmol/l) 0·98 1·03 1·06 1·00
SD 0·26 0·23 0·23 0·26
Unadjusted coeff. Ref. 0·046 0·078 0·018 0·42
Multivariable-adjusted β coeff.* Ref. 0·034 0·08 0·010 0·46
Multivariable-adjusted β coeff.† Ref. 0·034 0·08 0·011 0·47
Total cholesterol:HDL cholesterol‡
Participants (n) 109 110 111 109
Mean (mmol/l:mmol/l) 6·23 5·77 5·66 5·98
SD 2·24 1·75 1·75 1·73
Unadjusted coeff. Ref. −0·070 −0·084 −0·030 0·42
Multivariable-adjusted β coeff.* Ref. −0·051 −0·081 −0·015 0·56
Multivariable-adjusted β coeff.† Ref. −0·044 −0·073 −0·004 0·75
LDL cholesterol
Participants (n) 109 110 111 109
Mean (mmol/l) 4·23 4·17 4·28 4·24
SD 0·90 0·99 0·96 0·81
Unadjusted coeff. Ref. −0·062 0·047 0·010 0·72
Multivariable-adjusted β coeff.* Ref. −0·051 −0·081 −0·015 0·56
Multivariable-adjusted β coeff.† Ref. −0·044 −0·073 −0·004 0·75
TAG‡
Participants (n) 109 110 111 109
Mean (mmol/l) 2·27 2·13 1·74 1·79
SD 1·66 1·41 0·77 1·05
Unadjusted coeff. Ref. −0·078 −0·194 −0·197 0·001
Multivariable-adjusted β coeff.* Ref. −0·049 −0·172 −0·173 0·003
Multivariable-adjusted β coeff.† Ref. −0·032 −0·154 −0·148 0·01
Systolic blood pressure
Participants (n) 113 109 113 111
Mean (mmHg) 148·9 146·8 144·9 145·5
SD 26·8 0·3 22·6 21·2
Unadjusted coeff. Ref. −2·032 −3·973 −3·417 0·21
Multivariable-adjusted β coeff.* Ref. −0·233 −2·185 −2·083 0·40
Multivariable-adjusted β coeff.† Ref. −0·201 −2·15 −2·034 0·42
Diastolic blood pressure
Participants (n) 113 109 113 111
Mean, mmHg 86·2 84·3 84·1 83·0
SD 12·3 10·7 10·9 11·9
Unadjusted coeff. Ref. −1·873 −2·133 −3·194 0·04
Multivariable-adjusted β coeff.* Ref. −1·475 −1·865 −2·793 0·08
Multivariable-adjusted β coeff.† Ref. −1·340 −1·718 −2·587 0·11
Pulse pressure
Participants (n) 113 109 113 111
Mean (mmHg) 62·7 62·5 60·8 62·4
SD 20·0 16·1 18·2 16·0
Unadjusted coeff. Ref. −0·159 −1·84 −0·222 0·75
Multivariable-adjusted β coeff.* Ref. 1·242 −0·320 0·711 0·94
Multivariable-adjusted β coeff.† Ref. 1·139 −0·432 0·553 1·00
Coeff., coefficient; ref.; reference category.
*Multivariable-adjusted model 1, adjusted for age, BMI, social class (manual and non-manual workers), alcohol intake (non-drinker,
drinker has been divided into three equal groups), smokers (non-smoker, current smoker, previous smoker), leisure activity (yes and no)
and food energy intake.
†Multivariable-adjusted model 2, additionally adjusted for Ca intake.
‡Original data were transformed to natural logarithms for regression model.
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dose of cholecalciferol (vitamin D3) signiﬁcantly decreased
the concentration of serum TAG by 1·9mmol/l (P =0·02).
Several potential mechanisms for the observed inverse
association of vitamin D intake with serum TAG have been
proposed, namely the ability of vitamin D to modulate the
growth of vascular smooth muscle cells(25), antithrombotic
homeostasis(26) and inﬂammation markers of CVD(27).
Furthermore, previous studies(28,29) have reported that
vitamin D status (plasma 25-hydroxyvitamin D) is inver-
sely associated with TAG concentration; thus, to better
clarify how vitamin D status is related to CVD risk, future
biomarker studies of CVD and plasma 25-hydroxyvitamin
D are warranted.
However, it is not clear why the negative association
between vitamin D intake and plasma TAG was found at
5 years, but not after 10 years in the longitudinal analysis.
One possible explanation may be dietary change during
the follow-up period. One study(30) showed that there has
been a trend towards lower fat content in the UK diet since
the 1980s. As vitamin D is a fat-soluble vitamin(1), it is
likely that vitamin D intake has also declined and indeed
the current study showed vitamin D intake to be positively
associated with fat intake. Therefore the lack of
association between vitamin D intake and TAG con-
centration after 10 years may be due to vitamin D intake
declining over that period. In addition, we believe our
study is the ﬁrst to show a signiﬁcant positive cross-
sectional association between vitamin D intake and pulse
pressure, although no association was seen in the long-
itudinal analysis. A positive association between vitamin D
intake and DBP after over 20 years of follow-up was
observed, although no association was found for SBP. This
needs conﬁrmation in further studies.
There are very few studies that have reported associa-
tions between vitamin D intake and CVD risk or all-cause
mortality. Our null ﬁnding of vitamin D intake was consi-
stent with earlier prospective studies(12,13). The Iowa
Women’s Health Study (WHS) in 1999(12) similarly found
no association between vitamin D intake and IHD
mortality over an 8-year follow-up period and the study of
Bonthuis et al.(13) also reported vitamin D intake not to be
associated with CVD mortality or all-cause mortality during
14·4 years of follow-up. Furthermore, our study agrees
with a systematic review of ﬁfty-six randomised controlled
trails, which did not ﬁnd a signiﬁcant association between
vitamin D supplementation and total mortality risk(31).
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Table 4 Longitudinal analysis between baseline vitamin D intake and markers of CVD risk after 10 years of follow-up,
Caerphilly Prospective Cohort Study
Vitamin D intake from foods (µg/week)
Characteristic 0·1–9·9 10·0–15·1 15·2–27·2 ≥27·3 P for trend
TAG‡
Participants (n) 85 98 99 99
Mean (mmol/l) 2·13 2·08 1·80 1·78
SD 1·42 1·52 0·90 0·90
Unadjusted coeff. Ref. −0·048 −0·125 −0·132 0·06
Multivariable-adjusted β coeff.* Ref. −0·018 −0·102 −0·101 0·11
Multivariable-adjusted β coeff.† Ref. −0·004 −0·086 −0·077 0·20
Systolic blood pressure
Participants (n) 88 104 98 101
Mean (mmHg) 145·2 143·5 145·4 144·9
SD 23·7 21·3 22·1 22·2
Unadjusted coeff. Ref. −1·720 0·216 −0·271 0·89
Multivariable-adjusted β coeff.* Ref. −0·371 1·907 1·368 0·53
Multivariable-adjusted β coeff.† Ref. 0·142 2·416 2·191 0·39
Diastolic blood pressure
Participants (n) 88 104 98 101
Mean (mmHg) 82·2 80·6 83·0 81·1
SD 12·2 10·6 11·6 11·9
Unadjusted coeff. Ref. −1·613 0·809 −1·032 0·92
Multivariable-adjusted β coeff.* Ref. −1·281 0·899 −0·262 0·77
Multivariable-adjusted β coeff.† Ref. 0·877 1·300 0·385 0·52
Pulse pressure
Participants (n) 88 104 98 101
Mean (mmHg) 63·0 62·9 62·4 63·8
SD 18·2 17·5 16·3 17·1
Unadjusted ·coeff. Ref. −0·108 −0·593 0·761 0·81
Multivariable-adjusted β coeff.* Ref. 0·910 1·008 1·630 0·53
Multivariable-adjusted β coeff.† Ref. 1·019 1·117 1·805 0·50
Coeff., coefficient; ref., reference category.
*Multivariable-adjusted model 1, adjusted for age, BMI, social class (manual and non-manual workers), alcohol intake (non-drinker,
drinker has been divided into three equal groups), smokers (non-smoker, current smoker, previous smoker), leisure activity (yes and no)
and food energy intake.
†Multivariable-adjusted model 2, additionally adjusted for Ca intake.
‡Original data were transformed to natural logarithms for regression model.
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However, vitamin D intake (4·30 (SD 3·3) µg/d) was
reported in another 10-year follow-up prospective study of
361 men and 394 women(10) and suggested a protective
role of vitamin D intake on stroke, but not MI. The
contrasting ﬁndings of these studies may be due to
the different characteristics of the study participants. For
example, the initial mean ages of the subjects in the CAPS
(mean age of 51·7 years) and Iowa WHS(12) (mean age of
53·8 years) were similar, but age was higher (range 65–99
years) in the investigation of Marniemi et al.(10). Moreover,
the study of Sun et al.(11) showed vitamin D intake to be
associated with a lower risk of CVD in men, which may be
because the subjects in that study(11) had higher mean
vitamin D intake of 6 µg/d than subjects in the current
study (3 µg/d). Therefore, further research is needed to
conﬁrm the protective effect or otherwise of higher
vitamin D intake on CVD risk. In addition, whether there is
a sex-speciﬁc association between vitamin D intake and
CVD risk needs further investigation.
The recent report of the UK Scientiﬁc Advisory Com-
mittee on Nutrition(1) recommended a daily Reference
Nutrient Intake (RNI) of 10 µg vitamin D for the general
population aged 4 years and above, including pregnant
and lactating women. In CAPS, only eleven out of 452
subjects achieved the current RNI dose. The mean vitamin
D intake of 3 µg/d in the current study agrees well with the
P
u
b
lic
H
ea
lt
h
N
u
tr
it
io
n
Table 5 Longitudinal analysis between baseline vitamin D intake and markers of CVD risk after over 20 years of follow-
up, Caerphilly Prospective Cohort Study
Vitamin D intake from foods (µg/week)
Characteristic 0·1–9·9 10·0–15·1 15·2–27·2 ≥27·3 P for trend
Mean arterial pressure
Participants (n) 43 43 47 41
Mean (mmHg) 96·35 96·07 99·63 95·64
SD 10·19 14·07 13·09 13·70
Unadjusted coeff. Ref. −0·284 3·279 −0·702 0·82
Multivariable-adjusted β coeff.* Ref. 0·326 3·919 1·000 0·42
Multivariable-adjusted β coeff.† Ref. 0·985 4·556 1·937 0·28
Pulse wave velocity
Participants (n) 43 45 47 39
Mean (m/s) 11·89 11·40 11·77 11·48
SD 2·61 2·82 2·71 2·78
Unadjusted coeff. Ref. −0·495 −0·123 −0·411 0·66
Multivariable-adjusted β coeff.* Ref. −0·413 0·052 −0·098 0·89
Multivariable-adjusted β coeff.† Ref. −0·339 0·124 0·009 0·76
Augmentation index
Participants (n) 43 46 47 41
Mean (%) 27·35 25·30 27·04 24·70
SD 8·49 10·68 8·81 9·26
Unadjusted coeff. Ref. −2·044 −0·306 −2·654 0·36
Multivariable-adjusted β coeff.* Ref. −2·147 −0·37 −4·051 0·10
Multivariable-adjusted β coeff.† Ref. −1·389 0·363 −2·971 0·27
Systolic blood pressure
Participants (n) 43 46 47 41
Mean (mmHg) 143·3 141·9 143·7 139·8
SD 16·2 18·6 20·9 20·3
Unadjusted coeff. Ref. −1·368 0·379 −3·522 0·52
Multivariable-adjusted β coeff.* Ref. −0·055 1·225 −1·464 0·86
Multivariable-adjusted β coeff.† Ref. 0·971 2·218 −0·003 0·89
Diastolic blood pressure
Participants (n) 43 46 47 41
Mean (mmHg) 72·3 72·2 76·1 74·3
SD 9·2 11·5 10·4 12·0
Unadjusted coeff. Ref. −0·128 3·847 1·966 0·17
Multivariable-adjusted β coeff.* Ref. 0·141 4·378 3·574 0·04
Multivariable-adjusted β coeff.† Ref. 0·456 4·683 4·023 0·03
Pulse pressure‡
Participants (n) 43 46 47 41
Mean (mmHg) 71·0 69·8 67·5 65·5
SD 15·8 14·4 17·1 17·9
Unadjusted coeff. Ref. −0·013 −0·055 −0·087 0·06
Multivariable-adjusted β coeff.* Ref. 0·004 −0·047 −0·08 0·08
Multivariable-adjusted β coeff.† Ref. 0·014 −0·037 −0·066 0·13
Coeff., coefficient; ref., reference category.
*Multivariable-adjusted model 1, adjusted for age, BMI, social class (manual and non-manual workers), alcohol intake (non-drinker,
drinker has been divided into three equal groups), smokers (non-smoker, current smoker, previous smoker), leisure activity (yes and no)
and food energy intake.
†Multivariable-adjusted model 2, additionally adjusted for Ca intake.
‡Original data were transformed to natural logarithms for regression model.
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most recent published data from the UK National Diet and
Nutrition Survey(32), which reported the mean daily
vitamin D intake of 3·1 µg for men aged 19–64 years. Thus,
vitamin D-fortiﬁed foods need to be considered as a
possible strategy to facilitate population intake of the RNI.
Furthermore, a few recent studies have used higher doses
of vitamin D in their intervention trials(33–35), which also
showed no associations of vitamin D intake with CVD risk.
The strength of the CAPS is the long (over 20 years)
follow-up period. The current novel study presents both
cross-sectional and longitudinal relationships between
vitamin D intake and CVD risk. The longitudinal analysis
was conducted at 5 years, 10 years and over 20 years,
which provides the opportunity to test the consistency of
the inﬂuence of vitamin D intake on CVD events. There
are, however, several limitations of the study. One
potential limitation is that vitamin D intake was assessed at
baseline only and was not repeated during the follow-up
period to assess the extent of any diet change. Moreover,
CVD risk markers were not measured at the 10-year
follow-up. A further limitation in the present study was
that the results apply to men only, which may not repre-
sent associations in women. Finally, unknown residual
confounding factors may have inﬂuenced the outcomes
seen. In particular, vitamin D status of the subjects was not
measured initially or during the follow-up of CAPS and
there were no assessments of sunshine exposure; thus, it
was not possible to investigate the correlation between
vitamin D status and vitamin D dietary intake. In addition,
because the relatively small cohort size of the current
study may not be representative all UK men, further
prospective studies with large subject numbers would
provide more evidence on effect of the vitamin D intake
on CVD risk and/or all-cause mortality and possible
mechanisms of action.
Conclusions
The current investigation from CAPS, a prospective cohort
study, provides further evidence about the potential
beneﬁt of vitamin D intake on circulating TAG con-
centration. Additional studies are needed to verify the
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Table 6 Longitudinal analysis between baseline vitamin D intake and CVD risk (stroke, myocardial infarction (MI), heart failure (HF) and
all-cause mortality) after over 20 years of follow-up, Caerphilly Prospective Cohort Study
Non-adjusted Adjusted model 1* Adjusted model 2†
Vitamin D intake (µg/week) No. of men No. of strokes OR 95% CI OR 95% CI OR 95% CI
0·1–9·9 114 14 1·00 Ref. 1·00 Ref. 1·00 Ref.
10·0–15·1 112 21 1·65 0·79, 3·43 1·77 0·84, 3·76 1·67 0·79, 3·57
15·2–27·2 114 19 1·43 0·68, 3·01 1·58 0·74, 3·40 1·48 0·68, 3·20
≥27·3 112 18 1·37 0·64, 2·90 1·54 0·71, 3·37 1·41 0·64, 3·13
P for trend 0·54 0·36 0·51
Non-adjusted Adjusted model 1* Adjusted model 2†
Vitamin D intake (µg/week) No. of men No. of MI OR 95% CI OR 95% CI OR 95% CI
0·1–9·9 114 36 1·00 Ref. 1·00 Ref. 1·00 Ref.
10·0–15·1 112 37 1·07 0·61, 1·87 1·13 0·63, 2·02 1·11 0·62, 2·00
15·2–27·2 114 35 0·96 0·55, 1·68 1·09 0·61, 1·95 1·07 0·59, 1·93
≥27·3 112 34 0·94 0·54, 1·66 1·14 0·63, 2·07 1·12 0·61, 2·05
P for trend 0·76 0·71 0·76
Non-adjusted Adjusted model 1* Adjusted model 2†
Vitamin D intake (µg/week) No. of men No. of HF OR 95% CI OR 95% CI OR 95% CI
0·1–9·9 114 10 1·00 Ref. 1·00 Ref. 1·00 Ref.
10·0–15·1 112 13 1·37 0·57, 3·26 1·87 0·74, 4·72 1·66 0·65, 4·24
15·2–27·2 114 10 1·00 0·40, 2·50 1·19 0·45, 3·14 1·02 0·38, 2·73
≥27·3 112 10 1·02 0·41, 2·55 1·18 0·44, 3·15 0·95 0·35, 2·59
P for trend 0·85 0·99 0·66
Non-adjusted Adjusted model 1* Adjusted model 2†
Vitamin D intake (µg/week) No. of men No. of deaths OR 95% CI OR 95% CI OR 95% CI
0·1–9·9 114 76 1·00 Ref. 1·00 Ref. 1·00 Ref.
10·0–15·1 112 69 0·80 0·47, 1·38 0·84 0·46, 1·52 0·89 0·49, 1·64
15·2–27·2 114 65 0·66 0·39, 1·14 0·77 0·43, 1·39 0·82 0·46, 1·49
≥27·3 112 71 0·87 0·50, 1·50 0·98 0·53, 1·81 1·09 0·59, 2·03
P for trend 0·47 0·89 0·86
Ref. reference category.
OR derived from logistic regression.
*Model 1: multivariable-adjusted model adjusted for age, BMI, social class (manual and non-manual workers), alcohol intake (non-drinker, drinker has been
divided into three equal groups), smokers (non-smoker, current smoker, previous smoker), leisure activity (yes and no) and food energy intake.
†Model 2: additionally adjusted for Ca intake.
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current ﬁnding, especially randomised controlled inter-
vention trials on the effect of vitamin D intake on CVD risk
markers in subjects of low vitamin D status and mechan-
istic studies to determine the mode of action.
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